Xilio Therapeutics (XLO) Revenue & Revenue Breakdown
Xilio Therapeutics Revenue Highlights
Latest Revenue (Y)
$6.34M
Latest Revenue (Q)
$19.07M
Xilio Therapeutics Revenue by Period
Xilio Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $6.34M | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | - |
Xilio Therapeutics generated $6.34M in revenue during NA 2024, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Xilio Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $19.07M | 135.85% |
| 2025-06-30 | $8.08M | 175.90% |
| 2025-03-31 | $2.93M | 69.95% |
| 2024-12-31 | $1.72M | -23.82% |
| 2024-09-30 | $2.26M | -3.99% |
| 2024-06-30 | $2.36M | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $2.90M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | - |
Xilio Therapeutics generated $19.07M in revenue during Q3 2025, up 135.85% compared to the previous quarter, and up 808.91% compared to the same period a year ago.
Xilio Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| FGEN | FibroGen | $29.62M | $1.08M |
| LVTX | LAVA Therapeutics | $11.98M | - |
| XLO | Xilio Therapeutics | $6.34M | $19.07M |
| OKUR | OnKure Therapeutics | - | - |
| PDSB | PDS Bio | - | - |
| TVRD | Tvardi Therapeutics | - | - |
| KZR | Kezar Life Sciences | - | - |
| ALGS | Aligos Therapeutics | - | $965.00K |
| SKYE | Skye Bioscience | - | - |
| TPST | Tempest Therapeutics | - | - |